Patient attitudes regarding the cost of illness in cancer care

Oncologist

Volumn 20, Issue 10, 2015, Pages 1199-1204

  Meisenberg, Barry R ^a,b   Varner, Ashley ^a   Ellis, Erin ^c   Ebner, Stephen ^b   Moxley, John ^b   Siegrist, Erika ^b   Weng, David ^a  

^a ANNE ARUNDEL MEDICAL CENTER   (United States)

^b Anne Arundel Hospital   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Attitudes; Choice behavior; Cost of illness; Neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER PATIENT; CHEMORADIOTHERAPY; COST OF ILLNESS; FEMALE; FINANCIAL DEFICIT; HUMAN; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL ONCOLOGIST; PATIENT ATTITUDE; PATIENT PREFERENCE; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; SOCIOECONOMICS; VERY ELDERLY; ATTITUDE TO HEALTH; DOCTOR PATIENT RELATION; ECONOMICS; HEALTH SURVEY; MIDDLE AGED; NEOPLASMS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ATTITUDE TO HEALTH; COST OF ILLNESS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT PREFERENCE; PHYSICIAN-PATIENT RELATIONS; YOUNG ADULT;

EID: 84943255338     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0168     Document Type: Article

References (30)

1. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011;364:2060-2065.
2. KuehnBM. Economist: It's time for tough choices on US health costs. JAMA 2014;311:2469-2470.
3. Chino F, Peppercorn J, Taylor DH Jr. et al. Selfreported financial burden and satisfaction with care among patients with cancer. The Oncologist 2014;19: 414-420.
4. Bradley CJ. Financial hardship: A consequence of survivorship? J Clin Oncol 2012;30:1579-1580.
5. Sharp L, Carsin A-E, Timmons A. Associations between cancer-related financial stress and strain andpsychologicalwell-beingamongindividuals living with cancer. Psychooncology 2013;22:745-755.
6. Dusetzina SB, Winn AN, Abel GA et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014;32:306-311.
7. Zullig LL, Peppercorn JM, Schrag D et al. Financial distress, use of cost-coping strategies, and adherence to prescription medication among patients with cancer. J Oncol Pract 2013;9: 60s-63s.
8. Ubel PA, Abernethy AP, Zafar SY. Full disclosure- out-of-pocket costs as side effects. N Engl J Med 2013;369:1484-1486.
9. Meropol NJ, Schrag D, Smith TJ et al. American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 2009;27: 3868-3874.
10. Financial considerations. Available at http:// www.cancer.net/navigating-cancer-care/financialconsiderations. Accessed December 8, 2014.
11. Kaser E, Shaw J, Marven M et al. Communication about high-cost drugs in oncology-the patient view. Ann Oncol 2010;21:1910-1914.
12. Bestvina CM, Zullig LL, Rushing C et al. Patientoncologist cost communication, financial distress, and medication adherence. J Oncol Pract 2014;10: 162-167.
13. Irwin B, Kimmick G, Altomare I et al. Patient experience and attitudes toward addressing the cost of breast cancer care. The Oncologist 2014;19: 1135-1140.
14. Prawitz AD, Garman ET, Sorhaindo B et al. InCharge financial distress/financial well-being scale: Development, administration, and score interpretation. J Financial Counseling Plann 2006; 17:34-50.
15. Nielsen RB. Assessing financial wellness via computer-assisted telephone interviews. J Financial Counseling Plann 2010;21:16-29.
16. de Souza JA, Wong Y-N. Financial distress in cancer patients. JMed Pers 2013;11:73-77.
17. Head BA, Faul AC.Development and validation of a scale to measure socioeconomic well-being in persons with cancer. J Support Oncol 2008;6: 183-192.
18. Zafar SY,AbernethyAP. Financial toxicity, part I: A new name for a growing problem. Oncology (Williston Park) 2013;27:80-81, 149.
19. de Souza JA, Yap BJ, Hlubocky FJ et al. The development of a financial toxicity patient-reported outcomein cancer:TheCOSTmeasure.Cancer 2014; 120:3245-3253.
20. Longo CJ, Fitch M, Deber RB et al. Financial and family burden associated with cancer treatment in Ontario, Canada. Support Care Cancer 2006;14: 1077-1085.
21. Kodama Y, Morozumi R, Matsumura T et al. Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: A retrospective survey. BMC Cancer 2012; 12:152-161.
22. Zafar SY, Peppercorn JM, Schrag D et al. The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. The Oncologist 2013; 18:381-390.
23. Bullock AJ, Hofstatter EW, Yushak ML et al. Understanding patients' attitudes toward communication about the cost of cancer care. J Oncol Pract 2012;8:e50-e58.
24. Vater LB, Donohue JM, Arnold R et al.What are cancer centers advertising to the public?: A content analysis. Ann Intern Med 2014;160:813-820.
25. Neumann PJ, Palmer JA, Nadler E et al. Cancer therapy costs influence treatment: A national survey of oncologists. Health Aff (Millwood) 2010; 29:196-202.
26. Kelly RJ, Forde PM, Bagheri A et al. Measuring the impact of chemotherapy cost discussions between patients and providers at the time of prescribing. J Clin Oncol 2013;31(suppl 31):257a.
27. Shankaran V, Ramsey S. Addressing the financial burden of cancer treatment. JAMA Oncol 2015;1:273-274.
28. Jagsi R, Pottow JA, Griffith KA et al. Long-term financial burden of breast cancer: Experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 2014;32: 1269-1276.
29. Ekwueme DU, Yabroff KR, Guy GP Jr. et al. Medical costs and productivity losses of cancer survivors-United States, 2008-2011. MMWR Morb Mortal Wkly Rep 2014;63:505-510.
30. Schwarz N. Self-reports: How the questions shape the answers. Am Psychol 1999;54:93-105